Cargando…

Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study

AIM: We probed the prognostic value of the preoperative high-sensitivity modified Glasgow prognostic score (HS-mGPS), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) for patients with oral cavity squamous cell carcinoma (OSCC) to identify patients with the highest risk of havi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Yao-Te, Fang, Ku-Hao, Hsu, Cheng-Ming, Lai, Chia-Hsuan, Chang, Sheng-Wei, Huang, Ethan I., Tsai, Ming-Shao, Chang, Geng-He, Luan, Chih-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886616/
https://www.ncbi.nlm.nih.gov/pubmed/35242712
http://dx.doi.org/10.3389/fonc.2022.825967
_version_ 1784660704299581440
author Tsai, Yao-Te
Fang, Ku-Hao
Hsu, Cheng-Ming
Lai, Chia-Hsuan
Chang, Sheng-Wei
Huang, Ethan I.
Tsai, Ming-Shao
Chang, Geng-He
Luan, Chih-Wei
author_facet Tsai, Yao-Te
Fang, Ku-Hao
Hsu, Cheng-Ming
Lai, Chia-Hsuan
Chang, Sheng-Wei
Huang, Ethan I.
Tsai, Ming-Shao
Chang, Geng-He
Luan, Chih-Wei
author_sort Tsai, Yao-Te
collection PubMed
description AIM: We probed the prognostic value of the preoperative high-sensitivity modified Glasgow prognostic score (HS-mGPS), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) for patients with oral cavity squamous cell carcinoma (OSCC) to identify patients with the highest risk of having poor survival outcomes. MATERIALS AND METHODS: We executed a retrospective assessment of the records of 303 patients with OSCC who had been subjected to curative surgery between January 2008 and December 2017. The HS-mGPS was categorized using C-reactive protein and albumin thresholds of 3 mg/L and 35 g/L, respectively. Moreover, receiver operating characteristic curve analyses were executed to find out the optimal PLR and NLR cutoffs. We plotted survival curves and compared them through the use of the Kaplan–Meier method and log-rank test, respectively. Through a Cox proportional hazard model, we identified prognostic variables. We also plotted a nomogram comprising the HS-mGPS and clinicopathological factors and assessed its performance with the concordance index. RESULTS: The PLR and NLR cutoffs were 119.34 and 4.51, respectively. We noted an HS-mGPS of 1−2 to be associated with a shorter median overall survival (OS) and disease-fee survival (DFS) compared with an HS-mGPS of 0. Multivariate analysis revealed that an HS-mGPS of 1−2 and an NLR of ≥4.51 were independent risk factors related to poor OS and DFS. The HS-mGPS appeared to have better prognostic effect than did the PLR and NLR, and the combination of the HS-mGPS and NLR appeared to exhibit optimal discriminative ability for OS prognostication. The nomogram based on the HS-mGPS and NLR yielded accurate OS prediction (concordance index = 0.803). CONCLUSION: Our findings suggest that preoperative HS-mGPS is a promising prognostic biomarker of OSCC, and the nomogram comprising the HS-mGPS and NLR provided accurate individualized OSCC survival predictions.
format Online
Article
Text
id pubmed-8886616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88866162022-03-02 Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study Tsai, Yao-Te Fang, Ku-Hao Hsu, Cheng-Ming Lai, Chia-Hsuan Chang, Sheng-Wei Huang, Ethan I. Tsai, Ming-Shao Chang, Geng-He Luan, Chih-Wei Front Oncol Oncology AIM: We probed the prognostic value of the preoperative high-sensitivity modified Glasgow prognostic score (HS-mGPS), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) for patients with oral cavity squamous cell carcinoma (OSCC) to identify patients with the highest risk of having poor survival outcomes. MATERIALS AND METHODS: We executed a retrospective assessment of the records of 303 patients with OSCC who had been subjected to curative surgery between January 2008 and December 2017. The HS-mGPS was categorized using C-reactive protein and albumin thresholds of 3 mg/L and 35 g/L, respectively. Moreover, receiver operating characteristic curve analyses were executed to find out the optimal PLR and NLR cutoffs. We plotted survival curves and compared them through the use of the Kaplan–Meier method and log-rank test, respectively. Through a Cox proportional hazard model, we identified prognostic variables. We also plotted a nomogram comprising the HS-mGPS and clinicopathological factors and assessed its performance with the concordance index. RESULTS: The PLR and NLR cutoffs were 119.34 and 4.51, respectively. We noted an HS-mGPS of 1−2 to be associated with a shorter median overall survival (OS) and disease-fee survival (DFS) compared with an HS-mGPS of 0. Multivariate analysis revealed that an HS-mGPS of 1−2 and an NLR of ≥4.51 were independent risk factors related to poor OS and DFS. The HS-mGPS appeared to have better prognostic effect than did the PLR and NLR, and the combination of the HS-mGPS and NLR appeared to exhibit optimal discriminative ability for OS prognostication. The nomogram based on the HS-mGPS and NLR yielded accurate OS prediction (concordance index = 0.803). CONCLUSION: Our findings suggest that preoperative HS-mGPS is a promising prognostic biomarker of OSCC, and the nomogram comprising the HS-mGPS and NLR provided accurate individualized OSCC survival predictions. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8886616/ /pubmed/35242712 http://dx.doi.org/10.3389/fonc.2022.825967 Text en Copyright © 2022 Tsai, Fang, Hsu, Lai, Chang, Huang, Tsai, Chang and Luan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tsai, Yao-Te
Fang, Ku-Hao
Hsu, Cheng-Ming
Lai, Chia-Hsuan
Chang, Sheng-Wei
Huang, Ethan I.
Tsai, Ming-Shao
Chang, Geng-He
Luan, Chih-Wei
Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title_full Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title_fullStr Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title_full_unstemmed Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title_short Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study
title_sort prognostic role of high-sensitivity modified glasgow prognostic score for patients with operated oral cavity cancer: a retrospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886616/
https://www.ncbi.nlm.nih.gov/pubmed/35242712
http://dx.doi.org/10.3389/fonc.2022.825967
work_keys_str_mv AT tsaiyaote prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT fangkuhao prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT hsuchengming prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT laichiahsuan prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT changshengwei prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT huangethani prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT tsaimingshao prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT changgenghe prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy
AT luanchihwei prognosticroleofhighsensitivitymodifiedglasgowprognosticscoreforpatientswithoperatedoralcavitycanceraretrospectivestudy